3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Phase 2
1
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
2
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Nasopharyngeal Carcinoma
1
Inflammatory Breast Neoplasms
1
Fallopian Tube Neoplasms
1
Epstein-Barr Virus Infections
1
Endometrial Adenocarcinoma
1
Cystadenocarcinoma, Serous
1
Cholangiocarcinoma
1
Carcinoma, Non-Small-Cell Lung
1
Breast Carcinoma In Situ
1
Biliary Tract Neoplasms
1
Adenocarcinoma, Bronchiolo-Alveolar
1
Adenocarcinoma of Lung
1
Adenocarcinoma Of Esophagus
1
Interventions
Gemcitabine
4
Cisplatin
4
Capecitabine
4
Oxaliplatin
3
Leucovorin
2
Fluorouracil
2
Albumin-Bound Paclitaxel
2
titanium silicide
1
tegafur-gimeracil-oteracil
1
surufatinib
1
pembrolizumab
1
mitazalimab
1
durvalumab
1
cediranib
1
anlotinib
1
Taxes
1
S 1 (combination)
1
Paclitaxel
1
Folfox protocol
1
Control Groups
1
ARRY-334543
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Biliary Tract Neoplasms
×
Taxes
×
Clear all
NCT06037980
2025-02-17
PURITY
Gruppo Oncologico del Nord-Ovest
Phase 2/3
Recruiting
300 enrolled